Saturday, June 19, 2021
HomeHealthFDA OKs monoclonal antibody COVID-19 therapy for mild-to-moderate illness

FDA OKs monoclonal antibody COVID-19 therapy for mild-to-moderate illness

image 100365595 13642750

The Food and Drug Administration (FDA) on Wednesday granted emergency use authorization to a monoclonal antibody therapy to treat mild-to-moderate COVID-19 in adults and pediatric patients ages 12 and older who are considered at high risk for progression to severe disease. The therapy, sotrovimab, is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to the virus. Sotrovimab is a monoclonal antibody specifically directed against the spike protein of SARS-CoV-2 that is designed to block the virus’ attachment and entry into human cells. In clinical trials, the treatment was shown to reduce hospitalization or death in COVID-19 patients by 85%. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. OHIO WOMAN WINS $1 MILLION JACKPOT AND TEEN WINS FULL SCHOLARSHIP IN VACCINE LOTTERY”With the authorization of this monoclonal antibody treatment, we are providing another option to help keep high-risk patients with COVID-19 out of the hospital,” Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research, said. “It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of COVID-19 in the United States.” CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGEThe EUA allows for the therapy to be distributed and administered as a 500-milligram single dose intravenously by health care providers. Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. 

image 100365595 12891271

image 100365595 14413751



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Most Popular

Recent Comments